The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, RAPT Therapeutics Inc’s stock clocked out at $10.6, down -2.75% from its previous closing price of $10.9. In other words, the price has decreased by -$2.75 from its previous closing price. On the day, 0.54 million shares were traded. RAPT stock price reached its highest trading level at $11.1293 during the session, while it also had its lowest trading level at $10.22.
Ratios:
To gain a deeper understanding of RAPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.25 and its Current Ratio is at 13.25. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
H.C. Wainwright Upgraded its Neutral to Buy on December 26, 2024, while the target price for the stock was maintained at $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RAPT now has a Market Capitalization of 175300688 and an Enterprise Value of 9517616.
Stock Price History:
The Beta on a monthly basis for RAPT is -0.10, which has changed by -0.4137168 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, RAPT has reached a high of $26.56, while it has fallen to a 52-week low of $5.67. The 50-Day Moving Average of the stock is 10.33%, while the 200-Day Moving Average is calculated to be 9.03%.
Shares Statistics:
It appears that RAPT traded 114.33K shares on average per day over the past three months and 135300 shares per day over the past ten days. A total of 16.54M shares are outstanding, with a floating share count of 8.64M. Insiders hold about 47.75% of the company’s shares, while institutions hold 48.66% stake in the company. Shares short for RAPT as of 1753920000 were 435713 with a Short Ratio of 3.81, compared to 1751241600 on 485844. Therefore, it implies a Short% of Shares Outstanding of 435713 and a Short% of Float of 3.19.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of RAPT Therapeutics Inc (RAPT) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.72 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$1.02 and -$2.81 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$2.66, with 6.0 analysts recommending between -$1.58 and -$3.75.
